SC
ONCY

Scotia Capital’s Oncolytics Biotech ONCY Stock Holding History

Scotia Capital’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,679
Closed -$14.1K – 864
2023
Q4 		$14.1K Buy
+10,679
New +$16.7K ﹤0.01% 789
2020
Q2 		– Sell
-47,227
Closed -$66K – 706
2020
Q1 		$66K Hold
47,227
– – ﹤0.01% 610
2019
Q4 		$223K Sell
47,227
-812
-2% -$917 ﹤0.01% 672
2019
Q3 		$28K Hold
48,039
– – ﹤0.01% 711
2019
Q2 		$83K Buy
48,039
+3,329
+7% +$6.04K ﹤0.01% 698
2019
Q1 		$82K Buy
44,710
+221
+0.5% +$448 ﹤0.01% 672
2018
Q4 		$80K Buy
+44,489
New +$121K ﹤0.01% 630

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Scotia Capital's ONCY Position: Q1 2024 in Review

Scotia Capital sold out of Oncolytics Biotech (ONCY) in Q1 2024, closing a stake of 10,679 shares — an estimated $14.1K sold.

Scotia Capital first reported a position in ONCY in Q4 2018 and held it in 7 quarters. The position peaked at $223K in Q4 2019. 36 funds tracked by Wall St. Rank hold ONCY as of Q1 2024.

  • Scotia Capital reported no remaining Oncolytics Biotech position as of Q1 2024 after selling out during the quarter.
  • Scotia Capital sold 10,679 Oncolytics Biotech shares in Q1 2024, an estimated $14.1K.
  • Scotia Capital first reported a position in Oncolytics Biotech in Q4 2018 and held it in 7 quarters.
  • Scotia Capital's Oncolytics Biotech position peaked at $223K in Q4 2019.
  • 36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2024.

Based on Scotia Capital's 13F filing for Q1 2024, filed 14 May 2024.